Literature DB >> 34789479

Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.

Joseph E Grossman1,2, Lakshmi Muthuswamy1,2, Ling Huang1,2, Dipikaa Akshinthala1,2, Sofia Perea1,2, Raul S Gonzalez2,3, Leo L Tsai2,4, Jonah Cohen1,2, Bruno Bockorny1,2, Andrea J Bullock1,2, Benjamin Schlechter2,5, Mary Linton B Peters1,2, Catherine Conahan6, Supraja Narasimhan1, Christine Lim7, Roger B Davis1,2, Robert Besaw8, Mandeep S Sawhney1,2, Douglas Pleskow1,2, Tyler M Berzin1,2, Martin Smith2,4, Tara S Kent2,9, Mark Callery2,9, Senthil K Muthuswamy1,2, Manuel Hidalgo10.   

Abstract

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments are limited by toxicity. The HOPE trial (Harnessing Organoids for PErsonalized Therapy) was a pilot feasibility trial aiming to prospectively generate patient-derived organoids (PDO) from patients with PDAC and test their drug sensitivity and correlation with clinical outcomes. EXPERIMENTAL
DESIGN: PDOs were established from a heterogeneous population of patients with PDAC including both basal and classical PDAC subtypes.
RESULTS: A method for classifying PDOs as sensitive or resistant to chemotherapy regimens was developed to predict the clinical outcome of patients. Drug sensitivity testing on PDOs correlated with clinical responses to treatment in individual patients.
CONCLUSIONS: These data support the investigation of PDOs to guide treatment in prospective interventional trials in PDAC. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2022        PMID： 34789479      PMCID： PMC8866201          DOI： 10.1158/1078-0432.CCR-20-4116

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  37 in total

1.  Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft.

Authors:  M Pia Morelli; Emiliano Calvo; Esther Ordoñez; Michael J Wick; Belen-Rubio Viqueira; Pedro P Lopez-Casas; Elizabeth Bruckheimer; Antonio Calles-Blanco; David Sidransky; Manuel Hidalgo
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

2.  Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer.

Authors:  Ye Yao; Xiaoya Xu; Lifeng Yang; Ji Zhu; Juefeng Wan; Lijun Shen; Fan Xia; Guoxiang Fu; Yun Deng; Mengxue Pan; Qiang Guo; Xiaoxue Gao; Yuanchuang Li; Xinxin Rao; Yi Zhou; Liping Liang; Yaqi Wang; Jing Zhang; Hui Zhang; Guichao Li; Lixing Zhang; Junjie Peng; Sanjun Cai; Chen Hu; Jianjun Gao; Hans Clevers; Zhen Zhang; Guoqiang Hua
Journal:  Cell Stem Cell       Date:  2019-11-21       Impact factor: 24.633

3.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

Authors:  Chantal Pauli; Benjamin D Hopkins; Davide Prandi; Reid Shaw; Tarcisio Fedrizzi; Andrea Sboner; Verena Sailer; Michael Augello; Loredana Puca; Rachele Rosati; Terra J McNary; Yelena Churakova; Cynthia Cheung; Joanna Triscott; David Pisapia; Rema Rao; Juan Miguel Mosquera; Brian Robinson; Bishoy M Faltas; Brooke E Emerling; Vijayakrishna K Gadi; Brady Bernard; Olivier Elemento; Himisha Beltran; Francesca Demichelis; Christopher J Kemp; Carla Grandori; Lewis C Cantley; Mark A Rubin
Journal:  Cancer Discov       Date:  2017-03-22       Impact factor: 39.397

4.  Subtyping Pancreatic Cancer.

Authors:  Andrew V Biankin; Anirban Maitra
Journal:  Cancer Cell       Date:  2015-10-12       Impact factor: 31.743

5.  Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Authors:  Andrew J Aguirre; Jonathan A Nowak; Nicholas D Camarda; Richard A Moffitt; Arezou A Ghazani; Mehlika Hazar-Rethinam; Srivatsan Raghavan; Jaegil Kim; Lauren K Brais; Dorisanne Ragon; Marisa W Welch; Emma Reilly; Devin McCabe; Lori Marini; Kristin Anderka; Karla Helvie; Nelly Oliver; Ana Babic; Annacarolina Da Silva; Brandon Nadres; Emily E Van Seventer; Heather A Shahzade; Joseph P St Pierre; Kelly P Burke; Thomas Clancy; James M Cleary; Leona A Doyle; Kunal Jajoo; Nadine J McCleary; Jeffrey A Meyerhardt; Janet E Murphy; Kimmie Ng; Anuj K Patel; Kimberly Perez; Michael H Rosenthal; Douglas A Rubinson; Marvin Ryou; Geoffrey I Shapiro; Ewa Sicinska; Stuart G Silverman; Rebecca J Nagy; Richard B Lanman; Deborah Knoerzer; Dean J Welsch; Matthew B Yurgelun; Charles S Fuchs; Levi A Garraway; Gad Getz; Jason L Hornick; Bruce E Johnson; Matthew H Kulke; Robert J Mayer; Jeffrey W Miller; Paul B Shyn; David A Tuveson; Nikhil Wagle; Jen Jen Yeh; William C Hahn; Ryan B Corcoran; Scott L Carter; Brian M Wolpin
Journal:  Cancer Discov       Date:  2018-06-14       Impact factor: 39.397

6.  Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.

Authors:  Pascal Belleau; Dannielle D Engle; Hervé Tiriac; Dennis Plenker; Astrid Deschênes; Tim D D Somerville; Fieke E M Froeling; Richard A Burkhart; Robert E Denroche; Gun-Ho Jang; Koji Miyabayashi; C Megan Young; Hardik Patel; Michelle Ma; Joseph F LaComb; Randze Lerie D Palmaira; Ammar A Javed; Jasmine C Huynh; Molly Johnson; Kanika Arora; Nicolas Robine; Minita Shah; Rashesh Sanghvi; Austin B Goetz; Cinthya Y Lowder; Laura Martello; Else Driehuis; Nicolas LeComte; Gokce Askan; Christine A Iacobuzio-Donahue; Hans Clevers; Laura D Wood; Ralph H Hruban; Elizabeth Thompson; Andrew J Aguirre; Brian M Wolpin; Aaron Sasson; Joseph Kim; Maoxin Wu; Juan Carlos Bucobo; Peter Allen; Divyesh V Sejpal; William Nealon; James D Sullivan; Jordan M Winter; Phyllis A Gimotty; Jean L Grem; Dominick J DiMaio; Jonathan M Buscaglia; Paul M Grandgenett; Jonathan R Brody; Michael A Hollingsworth; Grainne M O'Kane; Faiyaz Notta; Edward Kim; James M Crawford; Craig Devoe; Allyson Ocean; Christopher L Wolfgang; Kenneth H Yu; Ellen Li; Christopher R Vakoc; Benjamin Hubert; Sandra E Fischer; Julie M Wilson; Richard Moffitt; Jennifer Knox; Alexander Krasnitz; Steven Gallinger; David A Tuveson
Journal:  Cancer Discov       Date:  2018-05-31       Impact factor: 38.272

7.  De novo compartment deconvolution and weight estimation of tumor samples using DECODER.

Authors:  Xianlu Laura Peng; Richard A Moffitt; Robert J Torphy; Keith E Volmar; Jen Jen Yeh
Journal:  Nat Commun       Date:  2019-10-18       Impact factor: 14.919

8.  Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.

Authors:  Richard A Moffitt; Raoud Marayati; Elizabeth L Flate; Keith E Volmar; S Gabriela Herrera Loeza; Katherine A Hoadley; Naim U Rashid; Lindsay A Williams; Samuel C Eaton; Alexander H Chung; Jadwiga K Smyla; Judy M Anderson; Hong Jin Kim; David J Bentrem; Mark S Talamonti; Christine A Iacobuzio-Donahue; Michael A Hollingsworth; Jen Jen Yeh
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

9.  Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer.

Authors:  Lucia Roa-Peña; Cindy V Leiton; Sruthi Babu; Chun-Hao Pan; Elizabeth A Vanner; Ali Akalin; Jela Bandovic; Richard A Moffitt; Kenneth R Shroyer; Luisa F Escobar-Hoyos
Journal:  Sci Rep       Date:  2019-08-02       Impact factor: 4.379

10.  PDX-derived organoids model in vivo drug response and secrete biomarkers.

Authors:  Ling Huang; Bruno Bockorny; Indranil Paul; Dipikaa Akshinthala; Pierre-Oliver Frappart; Omar Gandarilla; Arindam Bose; Veronica Sanchez-Gonzalez; Emily E Rouse; Sylvain D Lehoux; Nicole Pandell; Christine M Lim; John G Clohessy; Joseph Grossman; Raul Gonzalez; Sofia Perea Del Pino; George Daaboul; Mandeep S Sawhney; Steven D Freedman; Alexander Kleger; Richard D Cummings; Andrew Emili; Lakshmi B Muthuswamy; Manuel Hidalgo; Senthil K Muthuswamy
Journal:  JCI Insight       Date:  2020-11-05
View more
  5 in total

1.  Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring.

Authors:  Lotta Mäkinen; Markus Vähä-Koskela; Matilda Juusola; Harri Mustonen; Krister Wennerberg; Jaana Hagström; Pauli Puolakkainen; Hanna Seppänen
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

2.  Patient-derived organoids, creating a new window of opportunities for pancreatic cancer patients.

Authors:  Sandhya Sandhya; Tara L Hogenson; Martin E Fernandez-Zapico
Journal:  EMBO Mol Med       Date:  2022-03-14       Impact factor: 12.137

Review 3.  Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models.

Authors:  Qingfan Zheng; Bin Zhang; Changfeng Li; Xuewen Zhang
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

Review 4.  Tumor organoids: applications in cancer modeling and potentials in precision medicine.

Authors:  Hanxiao Xu; Dechao Jiao; Aiguo Liu; Kongming Wu
Journal:  J Hematol Oncol       Date:  2022-05-12       Impact factor: 23.168

Review 5.  Multicellular Modelling of Difficult-to-Treat Gastrointestinal Cancers: Current Possibilities and Challenges.

Authors:  Sarah K Hakuno; Ellis Michiels; Eleonore B Kuhlemaijer; Ilse Rooman; Lukas J A C Hawinkels; Marije Slingerland
Journal:  Int J Mol Sci       Date:  2022-03-15       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.